14th Apr 2014 10:02
LONDON (Alliance News) - Clinigen Group PLC said Monday that it has begun a named patient programme to provide Abiogen Pharma SpA's Nerixia to patients with Osteogenesis imperfecta.
Clinigen will supply the drug to countries in the EU, with the exception of Italy where it is already commercially available, via its global access programmes.
Osteogenesis imperfecta is a brittle bone disorder.
The treatment is not licenced outside of Italy, but under the programme will be available to healthcare professionals by request for individual patients who have no other approved option.
Shares in Clinigen were trading down 0.7% at 504.50 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
CLIN.L